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Andrew D. Blann, PHD, Gregory Y.H. Lip, MDA lthough they are valuable when used toreduce the risk of thrombosis in severaldiverse clinical conditions, the vitamin K
antagonists (VKAs) bring with them several chal-
lenges. These include the need for regular blood tests
(perhaps 4 to 6 times weekly), which are expensive
and inconvenient to manage; a narrow therapeutic
window; interactions with many other drugs; alcohol
and diet restrictions; teratogenicity; and a relatively
long half-life (making them insensitive in the face of
the need for a rapid change in activity). These and
other problems have led to the development of
other agents that do not act via vitamin K but directly
on coagulation pathway factors. Because they are
neither new nor novel these days, these agents are
called target-speciﬁc oral anticoagulants, direct oral
anticoagulants, and non–vitamin K oral anticoagu-
lants (NOACs) (1,2). In a recent European consensus
statement from the European Society of Cardiology
Working Group on Thrombosis Anticoagulation Task
Force, NOAC is the preferred acronym, which allows
web search engines (e.g., Medline, Google Scholar)
to ﬁnd older literature that previously used the
NOAC acronym (2).
An oft-cited advantage of these agents, compared
with VKAs, is that like antiplatelet drugs, no routine*Editorials published in the Journal of the American College of Cardiology
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numerous situations in which the precise anticoagu-
lant status of a particular patient is needed, such as
before emergency surgery or other invasive proce-
dure; in the face of evident or suspected hemorrhage;
when there is suspicion of overdose; in acute
thrombosis; in renal, liver, or heart failure; when
proof of compliance is required; in potential drug-
drug interactions; and in cases of trauma, acute
medical disease, and malignancy (3). In these cases,
some of which may be life threatening, the laboratory
needs to be able to offer some support.
In this respect, the problem is that the “standard”
laboratory coagulation tests of prothrombin time
(PT), activated partial thromboplastin time (APPT),
and thrombin time (TT) simply cannot do the job
adequately. Developed decades ago, these tests are
perfectly acceptable for assessing the effects of VKAs
and/or unfractionated heparin in many clinical situ-
ations. As effectively nonspeciﬁc screening tools,
they are unsuitable for the speciﬁc nature of the
NOACs that exert their effect in the direct inhibition
of thrombin (dabigatran) or factor Xa (rivaroxaban,
apixaban, and edoxaban) (3). Dabigatran certainly
prolongs “standard” PT; however, this effect has poor
sensitivity, varies according to different reagents,
and its relationship with APTT is curvilinear so that
neither of these tests are recommended (3,4). Simi-
larly, all 3 factor Xa inhibitors also prolong PT and
APTT but at low sensitivity. With careful choice of
reagents and analyzers, a modiﬁed PT can be used to
monitor the effects of rivaroxaban (5–8). The standard
TT is oversensitive for the assessment of dabigatran
(3,4); however, if the plasma is diluted (i.e., dilute
TT), TT can be used to monitor this drug (8,9). More
precise methods are ecarin clotting time (ECT) for
dabigatran (which has a correlation coefﬁcient of
0.92 with the plasma concentration of this drug,
compared with 0.86 for TT and 0.85 for PT) and
TABLE 1 Laboratory Monitoring of NOACs
NOAC Preferred Method In an Emergency
Dabigatran 1. Ecarin clotting time
2. Dilute thrombin time
APTT
(preferably with speciﬁc calibrated reagents)
Rivaroxaban Anti–factor Xa PT
(preferably with speciﬁc calibrated reagents)
Apixaban Anti–factor Xa Dilute PT
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1141methods based on anti–factor Xa activity for the fac-
tor Xa inhibitors (4,9–11).
Although there are British (3), European (10), and
U.S. recommendations (11), there is as yet no inter-
national consensus of the most effective tests for
each particular agent and no systematic overview of
the many research papers on this subject.Edoxaban Anti–factor Xa Few ﬁrm data
Opinion pooled from references 3, 10, and 11.
APTT ¼ activated partial thromboplastin time; NOAC ¼ non–vitamin K oral anticoagulant; PT ¼ prothrombin time.
SEE PAGE 1128This void has been ﬁlled by the report in this issue
of the Journal by Cuker et al. (12). Their systematic
review of up to 17 papers on dabigatran, rivaroxaban,
and apixaban conﬁrms the widely held view that the
standard PT and APTT tests are unsuitable but that
the dilute TT, ecarin-based assays (clotting and
chromogenic), and anti-Xa activity are preferred.
However, Cuker et al. (12) found some inconsistencies
between their overview and those of existing guide-
lines (3,11). Indeed, the ﬁeld is rapidly developing as
the 2014 update of the American Society of Hema-
tology guideline (11) suggests that in the presence of a
normal APTT, dabigatran is unlikely to contribute to
bleeding and that if the PT is normal, rivaroxaban is
unlikely to contribute to bleeding. Conversely, in the
presence of a prolonged APTT, dabigatran may be
contributing to bleeding, while if the PT is prolonged,
bleeding may be due to rivaroxaban. The guideline
fails to include apixaban in this opinion, but it sug-
gests the therapeutic levels of apixaban may not
elevate the PT and recommends the use of the dilute
TT, ECT, or anti–factor Xa assays for the measure-
ment of the anticoagulant activities of dabigatran
and the factor Xa inhibitors, respectively. Table 1
summarizes guidance on the test for each drug
(3,10,11).
So where does this leave the practitioner and the
hematologist? With continuing pressure on labora-
tory budgets, the PT and APTT would be methods of
choice but for their poor sensitivity and speciﬁcity
and the lack of consensus regarding most suitable
reagents and analyzers. However, their advantages ofrapid turnaround time and universal accessibility are
considerable, especially in an emergency setting. This
must be weighed against the increased demands of
the more complex ECT, dilute TT (the most cited
method being that of the HEMOCLOT technique
[3,4,9]), and the anti–factor Xa assays, which
although preferable on scientiﬁc grounds, are slower
and less accessible.
Until methods are widely agreed upon, each user
must decide which is most appropriate in their own
setting. The “fast and quick” tests (e.g., APTT and PT
for dabigatran and rivaroxaban, respectively) are
more qualitative and indicate an anticoagulant effect,
rather than quantify anticoagulation intensity. These
tests are certainly not for dose adjustment or assess-
ment of drug compliance. In the same way that we
have many options for oral anticoagulants and
may be able ﬁt the drug to the patient (and vice
versa), this choice now comes with the task of ﬁtting
the coagulation test to the type of NOAC drug used,
bearing in mind the urgency, practicality, and detail
needed.
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